Pharmacoscopy-guided Clinical Standard-of-care in r/r AML

Inclusion criteria * Patient with refractory or relapsed AML according to ELN2022 criteria. * Age 18-70 years. * Considered to be eligible for intensive chemotherapy. * Written informed consent. Exclusion criteria * Acute promyelocytic leukemia (APL) with PML-RARA or one of the other pathognomonic variant fusion genes/chromosome translocations. * Blast crisis after chronic myeloid leukemia (CML). * Considered not eligible for intensive chemotherapy. * Condition of the patient does not allow to wait for PCY results (patient requires immediate treatment). * PCY not working / patient sample did not pass the QC steps of PCY. * Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the principal investigator may interfere with the project or affect patient compliance. * Legal incompetence or Subjects lacking capacity to provide informed consent. * Participation in a clinical trial with an investigational drug within the 30 days preceding and during the present investigation.